Academic Journal
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
| العنوان: | Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer |
|---|---|
| المؤلفون: | Crown, J., Kennedy, M.J., Tresca, P., Marty, M., Espie, M., Burris, H.A., DeSilvio, M., Lau, M.R., Kothari, D., Koch, K.M., Diéras, V. |
| المساهمون: | GlaxoSmithKline |
| المصدر: | Annals of Oncology ; volume 24, issue 8, page 2005-2011 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2013 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/annonc/mdt222 |
| الاتاحة: | http://dx.doi.org/10.1093/annonc/mdt222 https://api.elsevier.com/content/article/PII:S0923753419368322?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753419368322?httpAccept=text/plain http://academic.oup.com/annonc/article-pdf/24/8/2005/13790097/mdt222.pdf |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| رقم الانضمام: | edsbas.F959C596 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdt222 |
|---|